Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Cooper

Showing results (111-120 of 140) with videos related to

Pageof 14
Sort By:
AAPS Pharmscitech|July 17, 2012
Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)Trevor Riley, David Christopher, Jan Arp, et al.
Diabetes, Obesity & Metabolism|April 14, 2021
Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER studyKamlesh Khunti, Bernard Charbonnel, Andrew Cooper, et al.
BMC Infectious Diseases|August 7, 2016
Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trialStephen D Persell, Jason N Doctor, Mark W Friedberg, et al.
Neurobiology of Disease|April 8, 2026
Restoring RCAN1 dosage mitigates sleep and EEG abnormalities in a down syndrome modelPeter Cain, Ryan Milstead, Mina Griffioen, et al.
Diabetes, Obesity & Metabolism|July 2, 2021
What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER studyFabrice Bonnet, Hungta Chen, Andrew Cooper, et al.
Endocrinology, Diabetes & Metabolism|January 14, 2022
Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort studySuzanne V Arnold, Kamlesh Khunti, Fengming Tang, et al.
Primary Care Diabetes|August 6, 2023
Considerations when planning and conducting large global observational studies: Experience from the DISCOVER study of patients with type 2 diabetesPernilla Aarskog, Javier Cid-Ruzafa, Hungta Chen, et al.
Diabetes Research and Clinical Practice|July 12, 2021
Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER studyLinong Ji, Fabrice Bonnet, Hungta Chen, et al.
Diabetes, Obesity & Metabolism|March 12, 2023
HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER studyBrenda Bongaerts, Oliver Kuss, Fabrice Bonnet, et al.
The British Journal of Ophthalmology|March 13, 2021
Eye health indicators for universal health coverage: results of a global expert prioritisation processIan McCormick, Islay Mactaggart, Serge Resnikoff, et al.
Pageof 14

Showing results (111-120 of 140) with videos related to

Sort By:
Pageof 14
AAPS Pharmscitech|July 17, 2012
Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs)Trevor Riley, David Christopher, Jan Arp, et al.
Diabetes, Obesity & Metabolism|April 14, 2021
Associations between second-line glucose-lowering combination therapies with metformin and HbA1c, body weight, quality of life, hypoglycaemic events and glucose-lowering treatment intensification: The DISCOVER studyKamlesh Khunti, Bernard Charbonnel, Andrew Cooper, et al.
BMC Infectious Diseases|August 7, 2016
Behavioral interventions to reduce inappropriate antibiotic prescribing: a randomized pilot trialStephen D Persell, Jason N Doctor, Mark W Friedberg, et al.
Neurobiology of Disease|April 8, 2026
Restoring RCAN1 dosage mitigates sleep and EEG abnormalities in a down syndrome modelPeter Cain, Ryan Milstead, Mina Griffioen, et al.
Diabetes, Obesity & Metabolism|July 2, 2021
What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin (≥7.0%) at initiation of second-line therapy? Results from the DISCOVER studyFabrice Bonnet, Hungta Chen, Andrew Cooper, et al.
Endocrinology, Diabetes & Metabolism|January 14, 2022
Impact of micro- and macrovascular complications of type 2 diabetes on quality of life: Insights from the DISCOVER prospective cohort studySuzanne V Arnold, Kamlesh Khunti, Fengming Tang, et al.
Primary Care Diabetes|August 6, 2023
Considerations when planning and conducting large global observational studies: Experience from the DISCOVER study of patients with type 2 diabetesPernilla Aarskog, Javier Cid-Ruzafa, Hungta Chen, et al.
Diabetes Research and Clinical Practice|July 12, 2021
Early versus late intensification of glucose-lowering therapy in patients with type 2 diabetes: Results from the DISCOVER studyLinong Ji, Fabrice Bonnet, Hungta Chen, et al.
Diabetes, Obesity & Metabolism|March 12, 2023
HbA1c trajectories over 3 years in people with type 2 diabetes starting second-line glucose-lowering therapy: The prospective global DISCOVER studyBrenda Bongaerts, Oliver Kuss, Fabrice Bonnet, et al.
The British Journal of Ophthalmology|March 13, 2021
Eye health indicators for universal health coverage: results of a global expert prioritisation processIan McCormick, Islay Mactaggart, Serge Resnikoff, et al.
Pageof 14